Budget delivers life-changing breast cancer medication for patients

Member for Forrest Nola Marino said the Turnbull Government has announced the listing of a life-changing breast cancer medicine on the Pharmaceutical Benefits Scheme that would otherwise cost patients around $71,820 per year in the Budget.

Mrs Marino said this investment of $703.6 million, will mean that more than 3,000 Australian patients with inoperable or metastatic hormone receptor positive breast cancer will benefit from the 1 July listing of ribociclib (Kisqali®).

“Hormone receptor positive tumours are the most common form of breast cancer and account for most of the deaths from the disease,” Mrs Marino said.

“We’re also providing a new cutting edge 3D mammography test for the early detection of breast cancer through Medicare.”

The independent Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing of Kisqali.

The Committee is by law and in practice, independent of Government in its deliberations. By law the Federal Government cannot list a new medicine without a positive recommendation from this committee.

Mrs Marino said since coming into Government, the Liberal-led Government has helped improve the health of Australians by subsidising approximately $9 billion worth of new medicines.

“Unlike Labor, we are subsidising all drugs recommended by the PBAC,” Mrs Marino said.

“Labor delayed the listing of seven vital drugs – leaving important medicines out of reach for many Australian patients.”